CYP19A1

CYP19A1 Full Name

cytochrome P450, family 19, subfamily A, polypeptide 1

CYP19A1 Introduction

CYP19A1 (cytochrome P450 family 19 subfamily A member 1), also known as aromatase, is a crucial steroidogenic enzyme that catalyzes the final step of estrogen biosynthesis by converting androgens into estrogens, including the conversion of testosterone to estradiol and androstenedione to estrone. As the only enzyme responsible for estrogen production in humans, CYP19A1 plays an essential role in maintaining hormonal balance across multiple tissues, including the ovaries, placenta, adipose tissue, brain, bone, and hormone-responsive organs. For researchers studying estrogen-related disorders, CYP19A1 is an important molecular target because abnormal aromatase expression or activity can alter local estrogen concentrations and contribute to disease development. The expression of CYP19A1 is highly tissue-specific and regulated by multiple promoter regions and transcriptional factors, allowing precise control of estrogen synthesis according to physiological requirements.

CYP19A1 plays a fundamental role in reproductive biology, endocrine regulation, and tissue homeostasis. In ovarian granulosa cells, CYP19A1 controls estrogen production during follicular development and directly influences oocyte maturation, ovulation, and fertility outcomes. Beyond reproduction, aromatase-mediated estrogen signaling contributes to bone remodeling, cardiovascular protection, brain function, and metabolic regulation. Dysregulated CYP19A1 activity can result in excessive or insufficient estrogen production, creating a molecular imbalance associated with conditions such as endometriosis, infertility, osteoporosis, and estrogen-dependent cancers, particularly breast and endometrial cancers. Because estrogen signaling is a major driver of many hormone-responsive diseases, CYP19A1 has become a clinically important target, with aromatase inhibitors widely used to reduce estrogen synthesis in specific cancer therapies and endocrine disorder management.

Alterations in CYP19A1 function, including genetic mutations or abnormal regulation, can lead to significant endocrine abnormalities. Loss-of-function mutations in CYP19A1 may cause aromatase deficiency, a rare inherited disorder characterized by impaired estrogen biosynthesis, androgen excess, abnormal sexual development, delayed bone maturation, and reproductive complications. Conversely, increased CYP19A1 expression or enhanced aromatase activity can promote local estrogen accumulation and support the progression of hormone-dependent pathological conditions. Current research continues to explore CYP19A1 as a valuable biomarker and therapeutic target for understanding estrogen-driven diseases, improving reproductive medicine strategies, and developing more precise approaches for hormone regulation. By clarifying CYP19A1-mediated estrogen pathways, researchers can better address challenges related to endocrine imbalance and advance targeted interventions for estrogen-associated disorders.

Alternate Names for CYP19A1

CYP19A1; cytochrome P450, family 19, subfamily A, polypeptide 1; ARO; ARO1; CPV1; CYAR; CYP19; CYPXIX; P-450AROM; aromatase; estrogen synthase; estrogen synthetase; cytochrome P-450AROM; cytochrome P450 19A1; microsomal monooxygenase; flavoprotein-linked monooxygenase; cytochrome P450, subfamily XIX (aromatization of androgens);

• 1.Kalantari S, et al.; Dynamic Regulation of CYP19A1 Promoter Region under Control of CREB Family Members in Endometrial Tissues of Women with Endometriosis: A Case-Control Study. Int J Fertil Steril. 2025, 19(2):151-156.
  2.Naseem A, et al.; Aromatase deficiency due to novel CYP19A1 mutation: a rare cause of maternal and fetal virilization. Case Rep Perinat Med. 2024, 13(1):20230032.